The study was sponsored by Janssen, the company developing canagliflozin. Dr. Schernthaner said that he has received honoraria and research funding from Janssen, AstraZeneca and Bristol-Myers Squibb, the companies developing dapagliflozin, and from Boehringer Ingelheim, the company developing empagliflozin. Dr. Zinman said that he has received honoraria and research funding from Johnson & Johnson (the parent company of Janssen), and Boehringer Ingelheim and other drug companies. Dr. Gallwitz said that he has received honoraria and research funding from Boehringer Ingelheim, AstraZeneca and Bristol-Myers Squibb, and other drug companies.
Conference Coverage
Canagliflozin Surpasses Sitagliptin as Diabetes Add-On
